Here's The Dark Side Of Trying To Find The Next Dendreon In The FDA Approval Lottery

If you’ll recall, Dendreon (DNDN) recently won FDA approval for Provenge, its prostate cancer drug and as a result, the stock soared double digits for a few days straight. Amateur investors and pros alike made a decent chunk of change going long on the stock.

But not all FDA announcements go the right way.

Check out Intermune (ITMN).

Trading was halted around 1pm as the stock sat at $45.44, down 5.41%. The big news was FDA approval/denial of its new drug Pirfenidone, a drug intended to treat idiopathic pulmonary fibrosis.

Unfortunately for the longs, the FDA says another clinical trial will be necessary before the product can be brought to market. As a result, the stock is down 80% in afterhours trading to $9.25.

The FDA approval lottery cuts both ways.

DNDN ITMN May 4

Photo: Google Finance

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.